Cameron’s $14.8 Billion Acquisition by Schlumberger
August 26, 2015
On August 26, 2015, Schlumberger Limited and Cameron jointly announced a definitive merger agreement in which the companies will combine in a stock and cash transaction valued at approximately $14.8 billion. Cravath represented Cameron in connection with this transaction. Under the terms of the agreement, Cameron shareholders will receive 0.716 shares of Schlumberger common stock and a cash payment of $14.44 in exchange for each Cameron share.
The Cravath team was led by partner George F. Schoen and included associates Rachael G. Coffey, Michael L. Arnold and Eric D. Rinder on M&A matters; partners Stephen L. Gordon and Lauren Angelilli and associate Ashley N. Elnicki on tax matters; partner Eric W. Hilfers and associates Jonathan J. Katz and Matthew J. Bobby on executive compensation and benefits matters; partner Christine A. Varney and associates Margaret Segall D’Amico and Jesse M. Weiss on antitrust matters; and partner Matthew Morreale on environmental matters.
Related Practices & Industries
People
- Photo
-
-
J.D., 1998, University of Chicago Law Schoolwith Honors
-
B.A., 1994, Cornell University
- New York
Education
Admitted In
-
J.D., 2000, Harvard Law Schoolcum laude
-
B.S., 1996, The Wharton School of the University of Pennsylvaniamagna cum laude
- New York
Education
Admitted In
- Photo
-
-
J.D., 1998, University of Chicago Law Schoolwith Honors
-
A.B., 1995, Princeton University
- New York
Education
Admitted In
- Photo
-
-
J.D., 1986, Georgetown University Law Center
-
M.P.A., 1982, Syracuse University
-
B.A., 1977, State University of New York, Albany
- New York
- District of Columbia
Education
Admitted In
- Photo
-
-
J.D., 1997, Columbia Law SchoolHarlan Fiske Stone Scholar
-
M.S., 1994, University of Pennsylvania
-
B.A., 1990, University of Pennsylvania
-
B.A.S., 1990, University of Pennsylvania
- New York
Education
Admitted In
- Photo
-
-
LL.M., 2013, New York University School of Law
-
J.D., 2007, Benjamin N. Cardozo School of LawOrder of the Coif, Dean's Distinguished Scholar, summa cum laude
-
B.S., 2003, Cornell University
- New York
Education
Admitted In
- Photo
-
-
J.D., 2008, Harvard Law Schoolcum laude
-
A.B., 2003, Harvard Collegemagna cum laude
- New York
Education
Admitted In
- Photo
-
-
J.D., 1981, Harvard Law Schoolcum laude
-
A.B., 1978, Cornell Universitycum laude
Education
Related News
Deals & Cases
October 04, 2024
DRI Healthcare Trust’s Acquisition of Payment Streams Based on the Cas9 Gene‑Editing Technology for CASGEVY®
On October 3, 2024, DRI Healthcare Trust, a global leader in providing financing to advance innovation in the life sciences industry, announced that one of its wholly owned subsidiaries acquired a portion of Editas Medicine, Inc.'s payment rights under a non‑exclusive license of Editas' Cas9 gene‑editing technology for CASGEVY®, the only approved gene‑edited cell therapy for sickle cell disease and transfusion‑dependent beta thalassemia, for an upfront purchase price of $57 million. The transaction entitles DRI Healthcare to specific payments based on a sublicensing agreement between Editas and Vertex Pharmaceuticals Incorporated. The payments include a share of the annual license fees that Vertex pays to Editas, which can range from $5 million to $40 million, including certain sales‑based annual license fee increases, and a portion of a $50 million contingent payment to which Editas is eligible under the Vertex sublicensing agreement. Cravath is representing DRI Healthcare in connection with the transaction.
Deals & Cases
September 05, 2024
Frontier’s $20 Billion Acquisition by Verizon
On September 5, 2024, Verizon Communications Inc. and Frontier Communications Parent, Inc. (“Frontier”), the largest pure‑play fiber provider in the U.S., announced they have entered into a definitive agreement for Verizon to acquire Frontier in an all‑cash transaction valued at $20 billion. Cravath is representing Frontier in connection with the transaction.
Deals & Cases
May 07, 2024
Ashland’s Sale of its Nutraceuticals Business to Turnspire Capital Partners
On May 7, 2024, Ashland Inc. (“Ashland”), a global additives and specialty ingredients company, announced that it has signed a definitive agreement to sell its nutraceuticals business to Turnspire Capital Partners LLC. Cravath is representing Ashland in connection with the transaction.
Deals & Cases
April 02, 2024
Endeavor’s $25 Billion Take‑Private Acquisition by Silver Lake
On April 2, 2024, Endeavor Group Holdings, Inc. (“Endeavor”), a global sports and entertainment company, announced that it has entered into a definitive agreement to be acquired by Silver Lake, the global leader in technology investing, in partnership with the Endeavor management team and additional anchor investors. Cravath is representing the independent Special Committee of Endeavor’s board of directors in connection with the transaction.
